A systematic review of secretin for children with autism spectrum disorders

Pediatrics

Volumn 127, Issue 5, 2011, Pages

  Krishnaswami, Shanthi ^a   McPheeters, Melissa L ^a,b   Veenstra VanderWeele, Jeremy ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autism spectrum disorders; Secretin

Indexed keywords

PLACEBO; SECRETIN;

AUTISM; CHILD; COGNITIVE DEFECT; COMMUNICATION DISORDER; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LANGUAGE DISABILITY; META ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL ADAPTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SECRETIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955518326     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-0428     Document Type: Review

References (19)

1. Tulassay Z, Bodnar A, Farkas I, Papp J, Gupta R. Somatostatin versus secretin in the treatment of actively bleeding gastric erosions. Digestion. 1992;51(4):211-216
2. Watanabe Y, Tsumura H, Sasaki H. Effect of continuous intravenous infusion of secretin preparation (secrepan) in patients with hemorrhage from chronic peptic ulcer and acute gastric mucosal lesion (AGML). Gastroenterol Jpn. 1991;26(suppl 3):86-89
3. Charlton CG, Miller RL, Crawley JN, Handel- mann GE, O'Donohue TL. Secretin modulation of behavioral and physiological functions in the rat. Peptides. 1983;4(5): 739-742
4. Fremeau RT Jr, Jensen RT, Charlton CG, Miller RL, O'Donohue TL, Moody TW. Secretin: specific binding to rat brain membranes. J Neurosci. 1983;3(8):1620-1625
5. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998; 9(1):9-15
6. Warren Z, Veenstra-VanderWeele J, Stone W, Bruzek JL, Nahmias AS, Foss-Feig JH, et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review No. 26. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-02-HHSA-290-2007-10065-I.) AHRQ Publication No. 11-EHC035-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: www. effectivehealthcare.ahrq. gov/reports/final. cfm. Accessed March 2011
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000
8. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000; 30(3):205-223
9. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659-685
10. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the effective healthcare program. J Clin Epidemiol. 2010;63(5): 513-523
11. Levy SE, Souders MC, Wray J, et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Arch Dis Child. 2003; 88(8):731-736
12. Molloy CA, Manning-Courtney P, Swayne S, et al. Lack of benefit of intravenous synthetic human secretin in the treatment of autism. J Autism Dev Disord. 2002;32(6): 545-551
13. Unis AS, Munson JA, Rogers SJ, et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry. 2002;41(11): 1315-1321
14. Owley T, McMahon W, Cook EH, et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry. 2001;40(11): 1293-1299
15. Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebocontrolled trial. Pediatrics. 2001;107(5). Available at: www.pediatrics.org/cgi/ content/full/107/5/e71
16. Coniglio SJ, Lewis JD, Lang C, et al. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr. 2001;138(5):649-655
17. Dunn-Geier J, Ho HH, Auersperg E, et al. Effect of secretin on children with autism: a randomized controlled trial. Dev Med Child Neurol. 2000;42(12):796-802
18. Chez MG, Buchanan CP, Bagan BT, et al. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord. 2000;30(2): 87-94
19. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005;(3): CD003495